✦ LIBER ✦

5082 Lapatinib (L) plus capecitabine (C) in HER2+ metastatic breast cancer (MBC): exploratory analyses by prior therapy

✍ Scribed by J. Crown; M.A. Casey; D. Cameron; B. Newstat; S.H. Stein

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of lapatinib plus cap

✍ Delea, Thomas E.; Tappenden, Paul; Sofrygin, Oleg; Browning, Dominy; Amonkar, Ma 📂 Article 📅 2011 🏛 Springer 🌐 French ⚖ 328 KB

2135 POSTER Cost-effectiveness (CE) of l

✍ T.E. Delea; P. Tappenden; O. Sofrygin; J. Karnon; M. Amonkar; D. Browning; H. Ru 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 64 KB

2009 POSTER Safety of the combination of

✍ A. Storniolo; M. Koehler; A. Preston; E. Rappold; J. Byrne; S. Stein; M. Ewer 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 63 KB

2096 ORAL Lapatinib (L) plus Capecitabin

✍ J. Crown; D. Cameron; A.M. Martin; B. Newstat; T. Pienkowski; A. Jagiello-Gruszf 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 59 KB

PCN9 VALIDITY OF PROPORTIONAL HAZARDS (P

✍ O Sofrygin; T Delea; P Tappenden; J Karnon; MM Amonkar; M Walker 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

5025 POSTER DISCUSSION Phase 3 Study of

✍ O'Shauqhnessv, J.; Telli, M.; Swain, S.; Gralow, J.; Rugo, H.; Litton, J.; Charp 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB